Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
October 29, 2001
- Drug Cost Ratio Down to 16.8% of Medical Cost for Outpatients in 1998
October 29, 2001
- Olympus Codevelops Ultrasound Surgical System with Intuitive Surgical of the US
October 29, 2001
- Glivec Recommended for Approval
October 29, 2001
- GEYMS Markets Fully-digital Ultrasound Diagnostic Equipment
October 29, 2001
- Dr Takemi, Lawmaker, Strongly Opposes Korosho, MOF Reform Plans
October 29, 2001
- Toshiba, NTT Com to Start ASP Services for Remote Imaging Diagnosis
October 29, 2001
- Korosho's NHI Price System Reform Is Full of Contradictions: Mr Yashiro of FPMAJ
October 29, 2001
- MEDICAL DEVICE NEWS IN BRIEF
October 29, 2001
- Korosho to Control Growth of Medical Spending for Elderly at All Medical Institutions
October 29, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 29, 2001
- METI's Position Paper Calls For Greater Freedom in Healthcare Services
October 29, 2001
- DIAGNOSTIC NEWS IN BRIEF
October 29, 2001
- REGULATORY NEWS IN BRIEF
October 29, 2001
- OTC NEWS IN BRIEF
October 29, 2001
- New Molecular Target-based Therapeutics for Lung Cancer Presented: AstraZeneca Seminar
October 29, 2001
- WORLD NEWS IN BRIEF
October 29, 2001
- Overseas Business Strategy of Domestic Firms Focused on:PMSRL Seminar
October 29, 2001
- Chugai Licenses in Polyglutamate Paclitaxel from CTI Technologies
October 29, 2001
- Meiji Seika to Codevelop Antibiotics with Kosan Biosciences in US
October 29, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…